cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2019-34-3-33-39cardiotomsk-810Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESРоль полиморфизмов генов ренин-ангиотензиновой системы в развитии углеводных нарушений у пациентов с артериальной гипертензиейThe role of the renin-angiotensin system gene polymorphisms in the development of carbohydrate disorders in patients with arterial hypertensionhttps://orcid.org/0000-0002-0051-3530ЖуравлеваЛ. В.ZhuravlyovaL. V.

д-р мед. наук, профессор, заведующий кафедрой внутренней медицины и эндокринологии № 3,

61022, Харьков, пр. Науки, 4

Dr. Sci. (Med.), Professor, Head of the Department of Internal Medicine and Endocrinology No. 3,

4, Nauky ave., Kharkiv, 61022

prof.zhuravlyova@gmail.comhttps://orcid.org/0000-0001-5507-5577КуликоваМ. В.KulikovaM. V.

канд. мед. наук, ассистент кафедры внутренней медицины и эндокринологии № 3,

61022, Харьков, пр. Науки, 4

Cand. Sci. (Med.), Assistant Professor, Department of Internal Medicine and Endocrinology No. 3,

4, Nauky ave., Kharkiv, 61022

medicl_2009@ukr.netХарьковский национальный медицинский университетУкраинаKharkiv National Medical UniversityUkraine2019011120193433339Copyright © Журавлева Л.В., Куликова М.В., 20192019Журавлева Л.В., Куликова М.В.Zhuravlyova L.V., Kulikova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/810

Артериальная гипертензия (АГ) и сахарный диабет (СД) 2-го типа являются наиболее распространенной коморбидной патологией. Сосуществование этих нарушений ускоряет развитие микро- и макрососудистых осложнений, значительно увеличивает сердечно-сосудистый риск, риск инсульта и терминальной стадии почечной недостаточности. Синергичность этих двух патологий обусловлена единством патогенетических механизмов, в том числе генетической предрасположенностью. Известно, что блокада ренин-ангиотензиновой системы (РАС) замедляет развитие СД 2-го типа, а также снижает частоту случаев кардиоваскулярных или почечных событий у больных с данными нарушениями. Полиморфизмы генов РАС активно изучаются в контексте развития кардиоваскулярных заболеваний. В настоящее время не установлена роль полиморфизмов этих генов в развитии углеводных нарушений, однако существует большая вероятность их участия. Цель обзора: проанализировать накопленные данные о влиянии полиморфизмов генов РАС на развитие АГ и СД 2-го типа.

Arterial hypertension and type 2 diabetes mellitus are the most widespread comorbid pathologies. The coexistence of these disorders accelerates the development of micro- and macrovascular complications, considerably increases the cardiovascular risk, as well as the risk of stroke and end stage renal disease. The synergism of these two pathologies is caused by the unity of pathogenetic mechanisms. Genetic predisposition also contributes to the development of both pathologies. It is well known that blockade of the renin-angiotensin system slows down the development of type 2 diabetes mellitus and also reduces the frequency of cardiovascular or kidney events in patients with these disorders. Gene polymorphisms of the reninangiotensin system are thoughtfully studied in the context of cardiovascular disease development. Currently, the role of gene polymorphisms in the development of carbohydrate disorders is not established, however, there is a high probability of their influence and importance. The purpose of review is to analyze the accumulated data on the effects of the renin-angiotensin system gene polymorphisms on the development of arterial hypertension and type 2 diabetes mellitus.

артериальная гипертензиясахарный диабет 2-го типаполиморфизмы генов ренин-ангиотензиновой системыarterial hypertensiontype 2 diabetes mellitusgene polymorphisms of the renin-angiotensin systemReferencesМедико-демографическая ситуация и основные показатели медицинской помощи населению в региональном аспекте: 2012 год. Киев: ГУ «Украинский институт стратегических исследований Минздрава Украины»; 2013:190.Medical-demographic situation and key indicators of medical care to the population in regional aspect: 2012. Kiev: PI “Ukrainian Institute of Strategic Researches of the Ministry of Health of Ukraine”; 2013:190 (In Ukr.).Нетяженко В.З., Амбросова Т.Н., Гидзинская И.Н., Ковалева О.Н., Мелина И.Н., Сиренко Ю.Н. и др. Артериальная гипертензия. Обновленный и адаптированный клинический протокол, основанный на доказательствах (2012). Рабочая группа по артериальной гипертензии Украинской ассоциации кардиологов. Артериальная гипертензия. 2012;1(21):96–152.Netyazhenko V.Z., Ambrosova T.N., Gidzinskaya I.N., Kovalyova O.N., Melina I.N., Sirenko Yu.N. et al. Arterial hypertension. The updated and adapted clinical protocol based on proofs (2012). Working group on arterial hypertension of the Ukrainian association of cardiologists. Arterial Hypertension. 2012;1(21):96–152 (In Ukr.).De Boer I.H., Bangalore S., Benetos A., Davis A.M., Michos E.D., Muntner P. et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273–1284. DOI: 10.2337/dci17-0026.De Boer I.H., Bangalore S., Benetos A., Davis A.M., Michos E.D., Muntner P. et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273–1284. DOI: 10.2337/dci17-0026.Мамедов М.Н., Горбунов Н.В., Кисeлева Н.В., Оганов Р.Г. Особенности структурно-функциональных изменений миокарда и гемодинамических нарушений у больных с метаболическим синдромом: вклад артериальной гипертонии в формирование суммарного коронарного риска. Кардиология. 2005;45(11):11–16.Mamedov M.N., Gorbunova N.V., Kisеleva N.V., Oganov R.G. Features of structurally functional changes of a myocardium and haemo dynamic violations at patients with a metabolic syndrome: contribution of an arterial hypertension to formation of total coronary risk. Kardiologiia. 2005;45(11):11–16. (In Russ.).Leoncini G., Ratto E., Viazzi F., Vaccaro V., Parodi D., Parodi A. et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J. Intern. Med. 2005;257: 454–460.Leoncini G., Ratto E., Viazzi F., Vaccaro V., Parodi D., Parodi A. et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J. Intern. Med. 2005;257: 454–460.Wei Y., Whaley–Connell А.Т., Chen К., Habibi J., Uptergrove G.M., Clark S.E. et al. NADPH oxidase contributes to vascular inflammation, insulin resistance and remodeling in the transgenic (mren2) rat. Hypertension. 2007;50:384–391.Wei Y., Whaley-Connell А.Т., Chen К., Habibi J., Uptergrove G.M., Clark S.E. et al. NADPH oxidase contributes to vascular inflammation, insulin resistance and remodeling in the transgenic (mren2) rat. Hypertension. 2007;50:384–391.Whaley-Connell A., Johnson M.S., Sowers J.R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog. Cardiovasc. Dis. 2010;52:401–409. DOI: 10.1016/j.pcad.2009.12.004.Whaley-Connell A., Johnson M.S., Sowers J.R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog. Cardiovasc. Dis. 2010;52:401–409. DOI: 10.1016/j.pcad.2009.12.004.Ермакова Е.А., Аметов А.С., Черникова Н.А. Сахарный диабет и артериальная гипертензия. Медицинский совет. 2015;12:12–17.Ermakova E.A., Ametov A.S., Chernikova N.A. Diabetes and arterial hypertension. Medical Council. 2015;12:12–17 (In Russ.).Callera G.E., Touyz R.M., Tostes R.C., Yogi A., He Y., Malkinson S. et al. Aldosterone activates vascular p38MAP kinase and NAD (P) H oxidase via c-Src. Hypertension. 2005;45:773–779.Callera G.E., Touyz R.M., Tostes R.C., Yogi A., He Y., Malkinson S. et al. Aldosterone activates vascular p38MAP kinase and NAD (P) H oxidase via c-Src. Hypertension. 2005;45:773–779.Giacchetti G. Aldosterone as key mediator of the cardiometabolic syndrome is primary aldosteronism: an observation study. J. Hypertens. 2007;25:177–186.Giacchetti G. Aldosterone as key mediator of the cardiometabolic syndrome is primary aldosteronism: an observation study. J. Hypertens. 2007;25:177–186.Kobayashi N., Yoshida К., Nakano S., Ohno T., Honda T., Tsubokou Y. et al. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension. 2006;47:671–679. DOI: 10.1161/01.HYP.0000203148.42892.7a.Kobayashi N., Yoshida К., Nakano S., Ohno T., Honda T., Tsubokou Y. et al. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension. 2006;47:671–679. DOI: 10.1161/01.HYP.0000203148.42892.7a.Heeneman E., Slumer J.C., Deamen M.G. Angiotensin-converting enzyme and vascular remodeling. Circ. Res. 2007;101:441–454. DOI: 10.1161/CIRCRESAHA.107.148338.Heeneman E., Slumer J.C., Deamen M.G. Angiotensin-converting enzyme and vascular remodeling. Circ. Res. 2007;101:441–454. DOI: 10.1161/CIRCRESAHA.107.148338.Henke N., Schmidt-Ulrich R., Dechend R. Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ. Res. 2007;101:268–276.Henke N., Schmidt-Ulrich R., Dechend R. Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ. Res. 2007;101:268–276.Дедов И.И., Шестакова М.В. Сахарный диабет и артериальная гипертензия. Москва: ООО «Медицинское информационное агентство»; 2006:344.Dedov I.I., Shestakova M.V. Diabetes and arterial hypertension. Moscow: Medical News Agency; 2006:344 (In Russ.).Muscogiuri G., Chavez A.O., Gastaldelli A. The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Current Vascular Pharmacology. 2011;6:301–312.Muscogiuri G., Chavez A.O., Gastaldelli A. The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Current Vascular Pharmacology. 2011;6:301–312.Sironi A.M., Sicari R., Folli F., Gastaldelli A. Ectopic fat storage, insulin resistance, and hypertension. Current Vascular Pharmacology. 2011;17:3074–3080.Sironi A.M., Sicari R., Folli F., Gastaldelli A. Ectopic fat storage, insulin resistance, and hypertension. Current Vascular Pharmacology. 2011;17:3074–3080.Jandeleit-Dahm K., Cooper M.E. Hypertension and diabetes: role of the renin-angiotensin system. Endocrinol. Metab. Clin. North Am. 2006;35:469–490. DOI: 10.1016/j.ecl.2006.06.007.Jandeleit-Dahm K., Cooper M.E. Hypertension and diabetes: role of the renin-angiotensin system. Endocrinol. Metab. Clin. North Am. 2006;35:469–490. DOI: 10.1016/j.ecl.2006.06.007.Новиков П.В. ДНК-тестирование: моногенные и мультифакториальные болезни. Русский медицинский журнал. 2011;12: 794–799.Novikov P.V. DNA testing: monogenic and multifactorial diseases. Russian Medical Journal. 2011;12:794–799 (In Russ.).Горбунова В.И. Медицинская генетика. СПб.: СПбГПУ; 2007:351.Gorbunova V.I. Medical genetics. Sankt-Peterburg: SPbGPU; 2007:351 (In Russ.).Forstermann U., Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708–1714. DOI: 10.1161/CIRCULATIONAHA.105.602532.Forstermann U., Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708–1714. DOI: 10.1161/CIRCULATIONAHA.105.602532.Song G.G., Lee Y.H. Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to systemic sclerosis: a meta-analysis. Genet. Mol. Res. 2014;13(4):74–83. DOI: 10.4238/2014.October.7.12.Song G.G., Lee Y.H. Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to systemic sclerosis: a meta-analysis. Genet. Mol. Res. 2014;13(4):74–83. DOI: 10.4238/2014.October.7.12.Kondo H., Ninomiya T., Hata J., Hirakawa Y., Yonemoto K., Arima H. et al. Angiotensin I-сonverting enzyme gene polymorphism enhances the effect of hypercholesterolemia on the risk of coronary heart disease in a general japanese population: the hisayama study. J. Atheroscler. Thromb. 2014;16:3078–3097. DOI: 10.5551/jat.24166.Kondo H., Ninomiya T., Hata J., Hirakawa Y., Yonemoto K., Arima H. et al. Angiotensin I-сonverting enzyme gene polymorphism enhances the effect of hypercholesterolemia on the risk of coronary heart disease in a general japanese population: the hisayama study. J. Atheroscler. Thromb. 2014;16:3078–3097. DOI: 10.5551/jat.24166.Abbas S.I., Raza S.T., Chandra A., Rizvi S., Ahmed F., Eba A. et al. Association of ACE, FABP2 and GST genes polymorphism with essential hypertension risk among a North Indian population. Ann. Hum. Biol. 2014;30:1–9. DOI: 10.3109/03014460.2014.968206.Abbas S.I., Raza S.T., Chandra A., Rizvi S., Ahmed F., Eba A. et al. Association of ACE, FABP2 and GST genes polymorphism with essential hypertension risk among a North Indian population. Ann. Hum. Biol. 2014;30:1–9. DOI: 10.3109/03014460.2014.968206.Bai Y., Wang L., Hu S., Wei Y. Association of angiotensin-converting enzyme I/D polymorphism with heart failure: a meta-analysis. Mol. Cell Biochem. 2012;361:297–304. DOI: 10.1007/s11010-011-1115-8.Bai Y., Wang L., Hu S., Wei Y. Association of angiotensin-converting enzyme I/D polymorphism with heart failure: a meta-analysis. Mol. Cell Biochem. 2012;361:297–304. DOI: 10.1007/s11010-011-1115-8.Pereira S.B., Velloso S.W., Chermont S., Quintão M.M., Nunes Abdhala R., Giro C. et al. β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity. Mol. Med. Report. 2013;7(1):259–265. DOI: 10.3892/mmr.2012.1120.Pereira S.B., Velloso S.W., Chermont S., Quintão M.M., Nunes Abdhala R., Giro C. et al. β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity. Mol. Med. Report. 2013;7(1):259–265. DOI: 10.3892/mmr.2012.1120.Mulder H.J., van Geel P.P., Schalij M.J., van Gilst W.H., Zwinderman A.H., Bruschke A.V. et al. DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial. Heart. 2003 May;89(5):557–558. DOI: 10.1136/heart.89.5.557.Mulder H.J., van Geel P.P., Schalij M.J., van Gilst W.H., Zwinderman A.H., Bruschke A.V. et al. DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial. Heart. 2003;89(5):557–558. DOI: 10.1136/heart.89.5.557.Sakhteh M.I., Poopak B., Amirizadeh N., Shamshiri A.R. Polymorphism and synergism of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) genes in coronary artery disease. Journal of the Renin-Angiotensin-Aldosterone System. 2015;16(4):1168– 1174. DOI: 10.1177/1470320314561247.Sakhteh M.I., Poopak B., Amirizadeh N., Shamshiri A.R. Polymorphism and synergism of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) genes in coronary artery disease. Journal of the Renin-Angiotensin-Aldosterone System. 2015;16(4):1168– 1174. DOI: 10.1177/1470320314561247.Keavney B., McKenzie C., Parish S. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/ deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS). Lancet. 2000;355:434–442.Keavney B., McKenzie C., Parish S. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/ deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS). Lancet. 2000;355:434–442.Govindaraju D.R., Adrienne Cupples L., Kannel W.B., O’Donnell C.J., Atwood L.D., D’Agostino R.B. et al. Genetics of the Framingham Heart Study Population. Adv. Genet. 2008;62:33–65. DOI: 10.1016/S0065-2660(08)00602-0.Govindaraju D.R., Adrienne Cupples L., Kannel W.B., O’Donnell C.J., Atwood L.D., D’Agostino R.B. et al. Genetics of the Framingham Heart Study Population. Adv. Genet. 2008;62:33–65. DOI: 10.1016/S0065-2660(08)00602-0.Schmieder R.E., Hilgers K.F., Schlaich M.P., Schmidt B.M. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208–1219.Schmieder R.E., Hilgers K.F., Schlaich M.P., Schmidt B.M. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208–1219.Целуйко В.И., Брегвадзе Т.Р., Мищук Н.Е., Вашакидзе З.С. Полиморфизм гена рецептора ангиотензина II 1-го типа и его влияние на эффективность терапии олмесартаном в пациентов с гипертонической болезнью. Український кардіологічний журнал. 2013;4:21–27.Tseluyko V.I., Bregvadze T.R., Mishchuk N.E., Vashakidze Z.S. Polimorfizm of a gene of a receptor of angiotensin of the II 1st type and its influence on efficiency of therapy olmesartany in patients with a hypertension. Ukrainian Cardiological Journal. 2013;4:21–27 (In Russ.).Bonnardeaux A., Davies E., Jeunemaitre X. Angiotensin II type 1 receptor gene polymorphisms in human essential. Hypertension. 1994;24:9–63.Bonnardeaux A., Davies E., Jeunemaitre X. Angiotensin II type 1 receptor gene polymorphisms in human essential. Hypertension. 1994;24:9– 63.Canavy I., Henry M., Morange P.E. Genetic polymorphisms and coronary artery disease in the south of France. Thromb. Haemost. 2000;83(2):212–216.Canavy I., Henry M., Morange P.E. Genetic polymorphisms and coronary artery disease in the south of France. Thromb. Haemost. 2000;83(2):212–216.Van Geel P.P., Pinto Y.M., Voors A.A. Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension. 2000;35:717–721.Van Geel P.P., Pinto Y.M., Voors A.A. Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension. 2000;35:717–721.Buraczyńska M., Pijanowski Z., Spasiewicz D., Nowicka T., Sodolski T., Widomska-Czekajska T. et al. Renin-angiotensin system gene polymorphisms: assessment of the risk of coronary heart disease. Kardiol. Pol. 2003;58(1):1–9.Buraczyńska M., Pijanowski Z., Spasiewicz D., Nowicka T., Sodolski T., Widomska-Czekajska T. et al. Renin-angiotensin system gene polymorphisms: assessment of the risk of coronary heart disease. Kardiol. Pol. 2003;58(1):1–9.Danser A.H., Schunkert H. Renin-angiotensin system gene polymorphisms: Potential mechanisms for their association with cardiovascular diseases. Eur. J. Pharmacol. 2000;410:303–316.Danser A.H., Schunkert H. Renin-angiotensin system gene polymorphisms: Potential mechanisms for their association with cardiovascular diseases. Eur. J. Pharmacol. 2000;410:303–316.Wang Q.S., Li Y.G., Chen J.F., Yu J.F., Wang J., Sun J. et al. Angiotensinogen polymorphisms and acquired atrial fibrillation in Chinese. J. Electrocardiol. 2010;43(4):373–377.Wang Q.S., Li Y.G., Chen J.F., Yu J.F., Wang J., Sun J. et al. Angiotensinogen polymorphisms and acquired atrial fibrillation in Chinese. J. Electrocardiol. 2010;43(4):373–377.Dickson M.E., Sigmund C.D. Genetic basis of hypertension: revisiting angioten-sinogen. Hypertension. 2007;48:14–20.Dickson M.E., Sigmund C.D. Genetic basis of hypertension: revisiting angioten-sinogen. Hypertension. 2007;48:14–20.Нгуен Т.Ч. Исследование ассоциации Т174М и M235T гена ангиотензиногена с ишемической болезнью сердца в Ростовской популяции. Фундаментальные исследования. 2010;3:114–121.Nguyen T.Ch. A research of T174M and M235T association of a gene of an andzhotenzinogen with coronary heart disease in the Rostov population. Basic Researches. 2010; 3:114–121 (In Russ.).Sethi A.A., Nordestgaard B.G., Gronholt M.L. Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease. Hypertension. 2003;6:102–111.Sethi A.A., Nordestgaard B.G., Gronholt M.L. Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease. Hypertension. 2003;6:102–111.Спивак И.М.,Сейлиева Н.А., Смирнова Т.Ю. Полиморфизмы генов ренин – ангиотензиновой системы и их корреляция с психологическими проявлениями родового стресса. Цитология. 2008;50(10):899–906.Spivak I.M., Seilieva N.A., Smirnova T.Yu. Polymorphisms of the genes of the renin – angiotensin system and their correlation with the psychological manifestations of generic stress. Citologija. 2008;50(10):899– 906 (In Russ.).Van Rijn M.J., Bos M.J., Isaacs A., Yazdanpanah M., Arias‐Vásquez A., Stricker B.H.Ch. et al. Polymorphisms of the renin – angiotensin system are assotiated with blood pressure, atherosclerosis and cerebral white matter pathology. J. Neurol. Neurosurg. Psychiatry. 2007;78:1083– 1087. DOI: 10.1136/jnnp.2006.109819.Van Rijn M.J., Bos M.J., Isaacs A., Yazdanpanah M., AriasVásquez A., Stricker B.H.Ch. et al. Polymorphisms of the renin – angiotensin system are assotiated with blood pressure, atherosclerosis and cerebral white matter pathology. J. Neurol. Neurosurg. Psychiatry. 2007;78:1083– 1087. DOI: 10.1136/jnnp.2006.109819.Ji L.D., Zhang L.N., Shen P. Association of angiotensinogen gene M235T and angiotensin-converting enzyme gene I/D polymorphisms with essential hypertension in Han Chinese population: a meta-analysis. J. Hypertens. 2010;28:419–428.Ji L.D., Zhang L.N., Shen P. Association of angiotensinogen gene M235T and angiotensin-converting enzyme gene I/D polymorphisms with essential hypertension in Han Chinese population: a meta-analysis. J. Hypertens. 2010;28:419–428.Fang Y.J., Deng H.B., Thomas G.N. Linkage of angiotensinogen gene polymorphisms with hypertension in a sibling study of Hong Kong Chinese. J. Hypertens. 2010;28:1203–1209.Fang Y.J., Deng H.B., Thomas G.N. Linkage of angiotensinogen gene polymorphisms with hypertension in a sibling study of Hong Kong Chinese. J. Hypertens. 2010;28:1203–1209.

The authors declare that there are no conflicts of interest present.